Inflarx Nv Stock In The News

IFRX Stock  USD 2.37  0.13  5.20%   
Our overall analysis of InflaRx NV's news coverage and content from conventional and social sources shows investors' bearish mood towards InflaRx NV. The specific impact of InflaRx NV news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of InflaRx NV's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using InflaRx NV headlines in addition to utilizing other, more conventional financial analysis modules. Check out InflaRx NV Backtesting and InflaRx NV Hype Analysis.
For more information on how to buy InflaRx Stock please use our How to Invest in InflaRx NV guide.

InflaRx NV Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
https://www.globenewswire.com/news-release/2025/01/23/3014168/0/en/InflaRx-Announces-Participation-in-Guggenheim-SMID-Cap-Biotech-Conference.html
 Neutral
Macroaxis News: globenewswire.com
InflaRx Receives European Commission App...
https://www.globenewswire.com/news-release/2025/01/15/3010292/0/en/InflaRx-Receives-European-Commission-Approval-for-GOHIBIC-vilobelimab-for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome-ARDS.html
 Neutral
Macroaxis News: globenewswire.com
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
https://www.globenewswire.com/news-release/2023/11/06/2773976/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-III-Trial-with-Vilobelimab-in-Pyoderma-Gangrenosum.html
 Bullish
Macroaxis News: globenewswire.com
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2023/11/01/2771018/0/en/InflaRx-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
 Bullish
Yahoo News
12 Best German Stocks To Buy Now
https://finance.yahoo.com/news/12-best-german-stocks-buy-231237201.html
 Bullish
Macroaxis News: globenewswire.com
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
https://www.globenewswire.com/news-release/2023/09/11/2740655/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Single-Ascending-Dose-SAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html
 Bullish
Macroaxis News: globenewswire.com
InflaRx’s Marketing Authorization Applic...
https://www.globenewswire.com/news-release/2023/08/30/2734224/0/en/InflaRx-s-Marketing-Authorization-Application-MAA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency-EMA.html
 Neutral
Macroaxis News: globenewswire.com
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
https://www.globenewswire.com/news-release/2023/08/10/2722561/0/en/InflaRx-Reports-Second-Quarter-2023-Financial-Results-Operating-Update.html
 Bullish
Macroaxis News: globenewswire.com
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
https://www.globenewswire.com/news-release/2023/06/28/2696083/0/en/InflaRx-Appoints-Dr-Camilla-Chong-as-Chief-Medical-Officer.html
 Bullish
Yahoo News
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
https://finance.yahoo.com/news/inflarx-appoints-dr-camilla-chong-113000371.html
 Bullish

InflaRx NV Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide InflaRx and other traded companies coverage with news coverage. We help investors stay connected with InflaRx headlines for the 24th of January to make an informed investment decision based on correlating the impacts of news items on InflaRx Stock performance. Please note that trading solely based on the InflaRx NV hype is not for everyone as timely availability and quick action are needed to avoid losses.
InflaRx NV's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help InflaRx NV investors visualize upcoming and past events in order to time the market based on InflaRx NV noise-free hype analysis.
InflaRx NV stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the InflaRx earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about InflaRx NV that are available to investors today. That information is available publicly through InflaRx media outlets and privately through word of mouth or via InflaRx internal channels. However, regardless of the origin, that massive amount of InflaRx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of InflaRx NV news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of InflaRx NV relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to InflaRx NV's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive InflaRx NV alpha.

InflaRx Largest EPS Surprises

Earnings surprises can significantly impact InflaRx NV's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-08
2024-06-30-0.2-0.24-0.0420 
2021-11-05
2021-09-30-0.31-0.270.0412 
2024-05-08
2024-03-31-0.22-0.170.0522 
2021-05-12
2021-03-31-0.23-0.180.0521 
2024-11-08
2024-09-30-0.2467-0.3-0.053321 
2017-12-21
2017-09-30-0.2-0.140.0630 
View All Earnings Estimates

InflaRx NV Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to InflaRx NV Stock. The global stock market is bullish. About 62% of major world exchanges and indexes are currently up. See today's market update for more information.
news
17th of January 2025
InflaRxs Buy Rating Reaffirmed at HC Wainwright
at thelincolnianonline.com 
Macroaxis News: globenewswire.com
15th of January 2025
InflaRx Receives European Commission Approval for GOHIBIC for the Treatment of SARS-CoV-2-...
at globenewswire.com 
Google News at Macroaxis
30th of December 2024
InflaRx Sees Large Growth in Short Interest - MarketBeat
at news.google.com 
Yahoo News
19th of November 2024
Is InflaRx N.V. the Best German Stock to Buy Now
at finance.yahoo.com 
news
12th of November 2024
HC Wainwright Reaffirms Buy Rating for InflaRx
at thelincolnianonline.com 
Google News at Macroaxis
31st of October 2024
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in...
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards InflaRx NV in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, InflaRx NV's short interest history, or implied volatility extrapolated from InflaRx NV options trading.

Additional Tools for InflaRx Stock Analysis

When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.